Get the Stockscreener App
133.32
23.55%
-41.06
Pre-market:
138.18
4.86
+3.65%
Moderna Inc stock is traded at $133.32, with a volume of 97.76M.
It is down -23.55% in the last 24 hours and up +124.10% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$174.38
Open:
$150.14
24h Volume:
97.76M
Relative Volume:
9.10
Market Cap:
$53.23B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-16.37
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+109.46%
1M Performance:
+124.10%
6M Performance:
+167.34%
1Y Performance:
+395.80%
1-Day Range:
$128.61
$155.00
1-Week Range:
$60.82
$176.66
52-Week Range:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
983,450 Shares in Moderna, Inc. $MRNA Bought by Deutsche Bank AG - MarketBeat
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In? - Yahoo Finance
5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go - CryptoRank
Moderna, Merck develop vaccine that could help fight against melanoma - cbs8.com
Moderna (MRNA) Sees Stock Surge After Positive Melanoma Trial Re - GuruFocus
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead - Yahoo Finance
Moderna chairman discusses cancer vaccine breakthrough - CNN
Moderna Inc (Derivatives) Price History and Historical Data - CoinMarketCap
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna, Walmart, Coinbase, Deere, SpaceX, Tesla, and More Stocks That Explain Today’s Market - Barron's
Trump grabbed up to $65,000 in Moderna stock. 2 weeks after an FDA approval, it rose 177% - moneywise.com
Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win - Barron's
U.S. Markets Dropped Thursday; Moderna Posted Biggest Loss - Barron's
Moderna (MRNA) Stock Looks Stretched With High Growth Already Priced In - Yahoo Finance
How Moderna’s Historic Short Squeeze Upended the AI Chip Trade - Barron's
Moderna Inc (Derivatives) to Chinese Yuan Price Today | Live MRNA to CNY Converter & Exchange Rate - CryptoRank
Historical Data for Moderna Inc (Derivatives) in USD - CryptoRank
Moderna Inc (Derivatives) Analytics: Price Dynamics, Quarterly Returns, and Annual Price Changes in USD - CryptoRank
Moderna Inc (Derivatives) Price | MRNA Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Moderna and Merck shares soar on mRNA cancer vaccine - Axios
Why investors should be paying attention to biotech - Yahoo Finance
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped - MarketWatch
Moderna Is Up 350% Since Our Recommendation. Here’s What to Do Next. - Barron's
Moderna’s Melanoma Result Landed On A Market Positioned The Other Way - Trefis
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
Moderna Breakthrough Sends MRNA Soaring: 4 mRNA Cancer Vaccine Stocks to Buy Instead - MarketWise
Freedom: Cancer vaccine opens a market of more than $240bn for Moderna - Freedom Broker
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History - TradingView
Why Is Moderna Stock Down Today? - Forbes
Merck Raises the Stakes for Pfizer's Cancer Vaccine AmbitionsModerna (NASDAQ:MRNA), Merck & Co (NYSE:M - Benzinga
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177% - Yahoo Finance
Biotech Is Booming, But These 2 Stocks Missed the MemoModerna (NASDAQ:MRNA), iShares Biotechnology ETF - Benzinga
Moderna (NASDAQ:MRNA) Shares Gap DownTime to Sell? - MarketBeat
Moderna, Merck Shares Soar on Cancer Vaccine Trial Success - Investing News Network
Personalized Vaccine Helped Melanoma Patients Stay Cancer-Free Longer, Drugmakers Say - U.S. News & World Report
Moderna pops on positive melanoma vaccine trial - Yahoo Finance
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips - Yahoo Finance
Moderna co-founder is a billionaire once again at $1.7 billion—he once turned down 20 high-paying job offers to ‘have more of an impact on the world’ - Yahoo Finance
Moderna Inc Stock (MRNA) Moved Down by 19.29% on Aug 20: Drivers Behind the Movement - TradingKey
New vaccine appears to prevent recurrence of the deadliest form of skin cancer - WEAU
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win - Yahoo Finance
Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst - Benzinga
Moderna says skin cancer vaccine trial a success - The Week
What Moderna & Merck's cancer vaccine breakthrough means for healthcare stocks - Yahoo Finance
Moderna stock analysis: mRNA cancer win meets zero-profit fundamentals - Investing.com
REGLeverage Shares PLC Leverage3XLongMrna$ Leverage3XLongMrna£Intraday Rebalance3x Long Moderna (MRNA) - TradingView
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade. - Barron's
Moderna’s Shift to Cancer Company Lifts Stock Up 177% - The New York Times
Moderna stock falls 20% after record rally as valuation concerns emerge - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):